Avidity Biosciences Inc. (RNA): Price and Financial Metrics

Avidity Biosciences Inc. (RNA): $18.54

-1.49 (-7.44%)

POWR Rating

Component Grades













Add RNA to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where RNA ranks best; there it ranks ahead of 35.81% of US stocks.
  • The strongest trend for RNA is in Growth, which has been heading up over the past 179 days.
  • RNA ranks lowest in Quality; there it ranks in the 8th percentile.

RNA Stock Summary

  • Of note is the ratio of AVIDITY BIOSCIENCES INC's sales and general administrative expense to its total operating expenses; only 7.71% of US stocks have a lower such ratio.
  • RNA's price/sales ratio is 135.93; that's higher than the P/S ratio of 97.93% of US stocks.
  • With a year-over-year growth in debt of 1,193.33%, AVIDITY BIOSCIENCES INC's debt growth rate surpasses 98.13% of about US stocks.
  • Stocks that are quantitatively similar to RNA, based on their financial statements, market capitalization, and price volatility, are LPTX, ATRA, INVZ, ENTA, and SLDB.
  • Visit RNA's SEC page to see the company's official filings. To visit the company's web site, go to www.aviditybiosciences.com.

RNA Valuation Summary

  • In comparison to the median Healthcare stock, RNA's price/earnings ratio is 133.16% lower, now standing at -6.5.
  • Over the past 28 months, RNA's EV/EBIT ratio has gone up 34.6.

Below are key valuation metrics over time for RNA.

Stock Date P/S P/B P/E EV/EBIT
RNA 2022-09-23 121.0 2.6 -6.5 -5.8
RNA 2022-09-22 130.7 2.8 -7.1 -6.3
RNA 2022-09-21 132.7 2.8 -7.2 -6.4
RNA 2022-09-20 138.4 3.0 -7.5 -6.7
RNA 2022-09-19 134.8 2.9 -7.3 -6.5
RNA 2022-09-16 135.9 2.9 -7.3 -6.6

RNA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RNA has a Quality Grade of D, ranking ahead of 5.58% of graded US stocks.
  • RNA's asset turnover comes in at 0.029 -- ranking 357th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows RNA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.029 1 21.496
2021-03-31 0.024 1 11.762
2020-12-31 0.024 1 8.416

RNA Price Target

For more insight on analysts targets of RNA, see our RNA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $46.40 Average Broker Recommendation 1.42 (Moderate Buy)

RNA Stock Price Chart Interactive Chart >

Price chart for RNA

RNA Price/Volume Stats

Current price $18.54 52-week high $29.25
Prev. close $20.03 52-week low $10.89
Day low $18.20 Volume 352,900
Day high $19.92 Avg. volume 303,542
50-day MA $19.73 Dividend yield N/A
200-day MA $17.64 Market Cap 966.43M

Avidity Biosciences Inc. (RNA) Company Bio

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe diseases. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.

RNA Latest News Stream

Event/Time News Detail
Loading, please wait...

RNA Latest Social Stream

Loading social stream, please wait...

View Full RNA Social Stream

Latest RNA News From Around the Web

Below are the latest news stories about AVIDITY BIOSCIENCES INC that investors may wish to consider to help them evaluate RNA as an investment opportunity.

Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), honors National Muscular Dystrophy Awareness Month, an annual observance that raises awareness for families across the nation who are living with neuromuscular diseases. This month Avidity will also raise awareness and support patient-focused activities for World Duchenne Awareness Day on September 7 and International Myo

Yahoo | September 7, 2022

Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Avidity management team will be participating at the following upcoming conferences:

Yahoo | September 1, 2022

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA) and Caribou Biosciences (CRBU)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avidity Biosciences (RNA – Research Report) and Caribou Biosciences (CRBU – Research Report) with bullish sentiments. Avidity Biosciences (RNA) In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Avidity Biosciences, with a price target of $29.00. The company's shares closed last Tuesday at $19.32. According to TipRanks.

Catie Powers on TipRanks | August 9, 2022

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Lags Revenue Estimates

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -24.32% and 4.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 9, 2022

Avidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the second quarter ended June 30, 2022 and highlighted recent corporate progress.

Yahoo | August 9, 2022

Read More 'RNA' Stories Here

RNA Price Returns

1-mo -15.50%
3-mo 27.42%
6-mo -0.11%
1-year -20.87%
3-year N/A
5-year N/A
YTD -22.00%
2021 -6.86%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5223 seconds.